EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Association of GLP ‐1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes

Yuqing Fan, Nan Peng, Linfeng Jiang, Ruolan Wei, Guoxian Lu, Shuo Zhang, Chen Mu, Mengyao Xue, Beini Lyu, Dongning Yao

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11194-11205

DOI: 10.1111/dom.71313 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Aims To compare cardiovascular, kidney, and liver outcomes of Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus seven other antidiabetic medications (ADMs) in Chinese patients with Type 2 diabetes. Materials and Methods This retrospective cohort study (2018–2024) used an Eastern China regional healthcare database. We included patients initiating GLP‐1 RAs, sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2 inhibitors), dipeptidyl peptidase‐4 inhibitors (DPP‐4 inhibitors), insulins, sulfonylureas, α‐glucosidase inhibitors (AGIs), thiazolidinediones, or meglitinides. Outcomes were major adverse cardiovascular (MACE), kidney (MAKE), and liver (MALO) events. A propensity score‐based matching weights (MWs) approach was used to balance covariates including demographics, comorbidities, and medication use, and Cox proportional hazards models were conducted in both intention‐to‐treat and per‐protocol analyses. Results Among 105 391 patients, SGLT‐2 inhibitors (HR 1.19, 95% CI 1.10–1.30), insulins (HR 1.42, 95% CI 1.32–1.52), sulfonylureas (HR 1.30, 95% CI 1.18–1.43), and AGIs (HR 1.45, 95% CI 1.31–1.59) were associated with higher MACE risk compared with GLP‐1 RAs. DPP‐4 inhibitors (HR 3.09, 95% CI 1.69–5.63), insulins (HR 6.11, 95% CI 4.37–8.54), and meglitinides (HR 4.56, 95% CI 2.32–8.97) were associated with higher MAKE risk. Higher MALO risk was observed with DPP‐4 inhibitors (HR 1.48, 95% CI 1.21–1.79), insulins (HR 2.06, 95% CI 1.81–2.34), AGIs (HR 1.55, 95% CI 1.26–1.90), and meglitinides (HR 1.43, 95% CI 1.07–1.92). Conclusions GLP‐1 RAs were associated with favourable cardio‐renal‐metabolic outcomes compared with several second‐line glucose‐lowering agents, particularly insulins and sulfonylureas. These findings add to the real‐world evidence supporting the potential cardiovascular, renal, and hepatic benefits of GLP‐1 RAs in patients with T2DM.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →